Insight

Improving Reporting Standards in Lung Cancer Trials

Lung Cancer/X

Dec 8, 2024, 04:24

Improving Reporting Standards in Lung Cancer Trials

Aakash Desai, Assistant Professor and Associate Director at UAB O’Neal Comprehensive Cancer Center, shared an article by William J. Phillips on LinkedIn:

“Improving Reporting Standards in Lung Cancer Trials.

A recent study published in International Association for the Study of Lung Cancer journal JTO (Articles in Press, Dec 4, 2024) highlights key gaps in reporting efficacy and toxicity in early-phase lung cancer trials:

88% of studies used subjective terms like “manageable” or “tolerable” (ISJET language) to describe toxicity.
Only 12% distinguished between Grade 1 and 2 adverse events (AEs), despite the growing relevance of chronic treatments.
These findings call for more objective and transparent reporting practices to align with modern oncology care needs. Better standards can lead to clearer data interpretation, benefiting researchers, clinicians, and patients alike.

The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments.

Authors: William J. Phillips, et al.

Improving Reporting Standards in Lung Cancer Trials

More posts featuring Aakash Desai.

Aakash Desai cancer IASLC International Association for the Study of Lung Cancer JTO Lung cancer OncoDaily Oncology UAB O'Neal Comprehensive Cancer Center William J. Phillips

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 1

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024

Have faith in yourself, and look out for the bad man - reflections from Neil Ranasinghe's involvement in LGCW

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

Eric Bouffet: New hope for children and adults with hemianopia

Special Coverage